| A decade of reversal: an analysis of 146 contradicted medical practices V Prasad, A Vandross, C Toomey, M Cheung, J Rho, S Quinn, SJ Chacko, ... Mayo Clinic Proceedings 88 (8), 790-798, 2013 | 434 | 2013 |
| The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses V Prasad, C Kim, M Burotto, A Vandross JAMA internal medicine 175 (8), 1389-1398, 2015 | 367 | 2015 |
| Characteristics of exceptional or super responders to cancer drugs V Prasad, A Vandross Mayo Clinic Proceedings 90 (12), 1639-1649, 2015 | 47 | 2015 |
| First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation EE Dumbrava, ML Johnson, AW Tolcher, G Shapiro, JA Thompson, ... J. Clin. Oncol 40 (16), 3003, 2022 | 35 | 2022 |
| Cardiovascular primary prevention: how high should we set the bar? V Prasad, A Vandross Archives of internal medicine 172 (8), 656-659, 2012 | 20 | 2012 |
| Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibition RM Hanna, M Barsoum, A Vandross, I Kurtz, R Burwick Current opinion in nephrology and hypertension 28 (3), 278-287, 2019 | 15 | 2019 |
| Case reports in the age of twitter AS Cifu, AL Vandross, V Prasad The American Journal of Medicine 132 (10), e725-e726, 2019 | 14 | 2019 |
| Publication trends among internal medicine residents and graduates V Prasad, J Rho, S Selvaraj, C Toomey, A Vandross, N Ho The American Journal of Medicine 125 (9), 939-944, 2012 | 12 | 2012 |
| Can a resident's publication record predict fellowship publications? V Prasad, J Rho, S Selvaraj, M Cheung, A Vandross, N Ho PloS one 9 (3), e90140, 2014 | 11 | 2014 |
| A decade of reversal V Prasad, A Vandross, C Toomey, M Cheung, J Rho, S Quinn, SJ Chacko, ... an analysis of 146 contradicted medical practices 2013, 88, 0 | 6 | |
| Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma A Vandross Seminars in Oncology 44 (6), 381-384, 2017 | 5 | 2017 |
| A phase 1/2 study of DCC-3116 as a single agent and in combination with trametinib in patients with advanced or metastatic solid tumors with RAS or RAF mutations. AW Tolcher, DS Hong, AL Vandross, CM Psoinos, DM Brennan, ... Journal of Clinical Oncology 40 (16_suppl), TPS3178-TPS3178, 2022 | 4 | 2022 |
| Early safety and efficacy from a phase I open-label clinical study of LVGN7409 (CD40 agonist antibody) in patients with advanced or metastatic malignancies. S Fu, AL Vandross, YH Hsu, N Shi, L Jiang, F Su, J Wang, CH Chan Journal of Clinical Oncology 40 (16_suppl), e14501-e14501, 2022 | 3 | 2022 |
| Inhibition of PI3K Alpha and PI3K delta with copanlisib shows preclinical activity as a single agent and in combination in multiple myeloma SM Larson, MY Peng, M Mead, A Vandross, D Conklin, E Von Euw, ... Blood 130, 3084, 2017 | 3 | 2017 |
| Failing to improve overall survival because post-protocol survival is long: fact, myth, excuse or improper study design? V Prasad, A Vandross Journal of Cancer Research and Clinical Oncology 140, 521-524, 2014 | 3 | 2014 |
| First-in-human dose-escalation study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with non-small cell lung, pancreatic, or colorectal cancer. AW Tolcher, AI Spira, JJ Nemunaitis, AL Vandross, H Mamdani, Z O'Brien, ... Journal of Clinical Oncology 41 (16_suppl), 3084-3084, 2023 | 2 | 2023 |
| A Phase 1 study of the anti-tissue factor antibody-drug conjugate XB002 in patients with advanced solid tumors (JEWEL-101): initial results from the dose-escalation stage S Ulahannan, ML Johnson, H Park, A Vandross, S Uttamsingh, J Li, ... European Journal of Cancer 174, S92-S93, 2022 | 2 | 2022 |
| ASCO Plenary Sessions: impact, legacy, future A Vandross, V Prasad, S Mailankody Seminars in Oncology 43 (3), 321-326, 2016 | 2 | 2016 |
| A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer. EY Yu, S Yazji, Y Katz, E Coates, LT Nordquist, AL Vandross, MA Salkeni, ... Journal of Clinical Oncology 42 (4_suppl), TPS241-TPS241, 2024 | 1 | 2024 |
| Updated phase 1 results from the PYNNACLE Phase 1/2 study of PC14586, a selective p53 reactivator, in patients with advanced solid tumors harboring a TP53 Y220C mutation AM Schram, GI Shapiro, ML Johnson, AW Tolcher, JA Thompson, ... MOLECULAR CANCER THERAPEUTICS 22 (12), 2023 | 1 | 2023 |
Vinay Prasad, MD MPHProfessor, University of California San FranciscoVerified email at ucsf.edu
